Study title: Nucl Med Commun. 2003 Mar;24(3):327-30. Erratum in: Nucl Med Commun. 2003 Apr;24(4):483. Differentiation of soft tissue haemangioma by 201Tl scintigraphy. Higuchi T, Taki J, Nakajima K, Kinuya S, Nonomura A, Tsuchiya H, Bunko H, Namura M, Tonami NNucl Med Commun. 2003 Mar;24(3):327-30. Erratum in: Nucl Med Commun. 2003 Apr;24(4):483. Differentiation of soft tissue haemangioma by 201Tl scintigraphy. Higuchi T, Taki J, Nakajima K, Kinuya S, Nonomura A, Tsuchiya H, Bunko H, Namura M, Tonami N
| Type of medicine: Medicines containing chemical active substances | |||||
| Therapeutic area: Diagnosis [E01] | |||||
| Brands: | |||||
| MAH holders: Please see report | |||||
| Assessment: | |||||
| Active substance: THALLIUM 201T1 CHLORIDE | |||||
| ATC code: V09GX01 | |||||
| Document link: | |||||
| Document date: | |||||
| Study number: | |||||
| EudraCT number: | |||||
| Scope of study: Clinical | |||||
| Population of study subjects: | Preterm newborn Infants | Newborn infants (1 to 27 days) | Infants and toddlers (28 days to 24 months) | Children (2 to 11 years) | Adolescents (12 to 18 years) |
| - | - | - | - | - | |